A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Sabeena, Karim, Mohammad Mahbubul, Ross, Allen G., Hossain, Mohammad Sharif, Clemens, John D., Sumiya, Mariya Kibtiya, Phru, Ching Swe, Rahman, Mustafizur, Zaman, Khalequ, Somani, Jyoti, Yasmin, Rubina, Hasnat, Mohammad Abul, Kabir, Ahmedul, Aziz, Asma Binte, Khan, Wasif Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709596/
https://www.ncbi.nlm.nih.gov/pubmed/33278625
http://dx.doi.org/10.1016/j.ijid.2020.11.191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709596/
https://www.ncbi.nlm.nih.gov/pubmed/33278625
http://dx.doi.org/10.1016/j.ijid.2020.11.191

Ejemplares similares